Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432449 | 0.88 | MAPT (0.47) | MAPTPOLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4432459 | 0.75 | MAPT (0.46) | MAPTPOLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4425893 | 0.73 | MAPT (0.44) | MAPTPOLBSLC6A4SLC6A2LMNA | |
| SCHEMBL29938335 | 0.73 | MAPT (0.45) | MAPTPOLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4428141 | 0.73 | MAPT (0.45) | MAPTPOLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27411071 | 0.72 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL28208319 | 0.70 | POLB (0.48) | MAPTPOLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4435056 | 0.70 | POLB (0.43) | MAPTPOLBLMNAALDH1A1 | |
| SCHEMBL27410911 | 0.70 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4426588 | 0.70 | MAPT (0.42) | MAPTPOLBSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217997-A1 | NOVEL MEPICIDES AS ANTIMICROBIAL AGENTS | GEORGE MASON UNIVERSITY | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217997-A1 | NOVEL MEPICIDES AS ANTIMICROBIAL AGENTS | SMPD1, MLYCD, SMPD3 | MAPT 4119/4885POLB 994/4885SLC6A4 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.